AR and neoplasm: Precise determination of the respective prevalence of individual AR mutations and their variation along treatment duration should now be more readily feasible using blood-based assays and the BEAMing technology described here, compared to analysis of CTCs which is not yet routinely established in the clinic, or of tumor biopsies which is challenging, especially in the case of metastases.